JSON
Assaf S, Stenberg H, Jesenak M, Tarasevych SP, Hanania NA, Diamant Z
Respir Med 218 (-) 107373 [2023-08-10; online 2023-08-10]
Since its global invasion in 2019, COVID-19 has affected several aspects of patients' lives and posed a significant impact on the health care system. Several patient populations were identified to be at high risk of contracting SARS-CoV-2 infection and/or developing severe COVID-19-related sequelae. Conversely, anyone who has contracted SARS-CoV-2 is at risk to experience symptoms and signs consistent with post-COVID manifestations. Patients with asthma were initially thought to be at increased risk and severity for SARS-CoV-2 infection. However, accumulating evidence demonstrates that asthma endotypes/phenotypes and comorbidities influence the risk stratification in this population. Furthermore, initial concerns about the potentially increased risk of poor outcomes with asthma treatments such as inhaled corticosteroids and biologics have not been substantiated. In this review, we provide an update on COVID-19 and asthma, including risk of susceptibility, clinical manifestations and course in this population as well as discuss recommendations for management.
PubMed 37567514
DOI 10.1016/j.rmed.2023.107373
Crossref 10.1016/j.rmed.2023.107373
pii: S0954-6111(23)00261-5